11 Best Pot Stocks to Buy According to Hedge Funds

Page 8 of 10

3. Incannex Healthcare Inc. (NASDAQ:IXHL)

On February 25, Incannex Healthcare Inc. (NASDAQ:IXHL) announced that its board of directors approved a 1-for-30 reverse stock split of the company’s common stock. The reverse split had previously been approved by stockholders at a special meeting held on May 27, 2025. The split will take legal effect at 4:01 p.m. Eastern Time on February 26, 2026, with trading on a split-adjusted basis commencing February 27, 2026, under a new CUSIP number on The Nasdaq Capital Market while retaining the ticker symbol “IXHL.” The stated purpose of the reverse split is to increase the per-share trading price of the company’s common stock to regain compliance with Nasdaq’s minimum bid price requirement for continued listing, thereby preserving exchange listing status and access to public capital markets.

On January 29, Incannex Healthcare Inc. (NASDAQ:IXHL) also announced the appointment of three additional members to its Clinical Advisory Board: Murray Stein, MD, MPH; Andrew Cutler, MD; and Amir Kalali, MD. The Clinical Advisory Board was established to provide independent scientific and clinical guidance as the company advances PSX-001 into its next phase of clinical and regulatory development. The board will advise on trial design, endpoint selection, regulatory strategy, and overall development planning, supporting disciplined progression through clinical milestones.

Incannex Healthcare Inc. (NASDAQ:IXHL) is a clinical-stage biopharmaceutical company focused on developing combination therapeutics targeting underlying biological pathways, including medicinal cannabis and psychedelic-based therapies.

Page 8 of 10